In a large platform of patient-derived tumor xenografts (PDTX), Bertotti and colleagues showed a significantly higher prevalence of HER2 gene amplification in cetuximab-resistant RAS, BRAF, and PIK3CA wild-type tumors [114]. Here, ERBB2 is linked to neoplasm.